drugset / Trial / NCT00638313
Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects
RandomizedSingle-groupTriple-blindTreatment
Summary
PF 04603629 is a long acting exendin proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and glucose lowering capabilities following a single subcutaneous dose.
Timeline
- Start
- 2007-08
- Primary completion
- —
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04603629 | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | PF-04603629 | Protein / enzyme biologic | 70 mg | Subcutaneous |